BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, have partnered to provide integrated drug substance and drug product solutions for biologics developers.
 
This alliance enables BioCina to offer high quality fill-and-finish solutions to their clients, to convert the drug substance produced at its Adelaide, South Australia facility into ready-to-use drug product at NovaCina’s advanced facility in Perth, Australia. This collaboration marks a milestone in providing end-to-end biopharmaceutical manufacturing solutions to clients worldwide.
 
As a result of this partnership, BioCina’s clients can benefit from NovaCina’s decades of clinical and commercial fill-and-finish experience, backed by numerous regulatory approvals, including from the U.S. Food and Drug Administration (FDA).
 
BioCina’s chief executive officer & member of NovaCina Board of Directors, Mark W. Womack, said, “BioCina is excited to partner with NovaCina, integrating our globally recognized expertise in clinical and commercial process development and drug substance manufacturing with their esteemed drug product services. This partnership promises to deliver unparalleled quality, adherence to the highest regulatory standards, and on-time delivery of client programs, setting a new benchmark in the market.”
 
NovaCina’s chief executive officer, Cyrus K. Mirsaidi, stated, “We are very excited to form this partnership with BioCina. Together, we provide a seamless end-to-end offering. At NovaCina, we are delighted to bring our world-class quality and safety to this value-adding collaboration.”

More BioCina News